Respiratory syncytial virus mutants, fusion peptides, particles, nucleic acids, pharmaceutical compositions and methods of use

By developing recombinant RSV G protein and virus-like particles containing specific mutations and combining them with appropriate adjuvants for immunization, the problems of unsatisfactory efficacy and safety risks of existing RSV vaccines have been solved, achieving highly efficient RSV infection prevention and treatment.

CN121752586APending Publication Date: 2026-03-27EMORY UNIVERSITY +1
2 Cites 0 Cited by

Patent Information

Application Number
CN202480055611.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-07-07
Filing Date
2024-07-05
Publication Date
2026-03-27

AI Technical Summary

Technical Problem

Existing RSV vaccines and therapies, such as palizumab, have limited efficacy and side effects. Live virus vaccines pose high safety risks, making it difficult to develop adequately attenuated and immunogenic RSV vaccines for children. Furthermore, existing RSV vaccination outcomes are not ideal.

Method used

Develop recombinant RSV G proteins containing specific mutations or fusion protein arrangements, bind to virus-like particles (VLPs) composed of RSV-F or RSV-G, and express them via nucleic acid encoded by a heterologous promoter, then immunize them using aluminum adjuvants and squalene oil-in-water emulsion adjuvants.

Benefits of technology

It enhances the immunogenicity and anti-attack protection against RSV, induces the production of potent antibodies, reduces viral load, and minimizes side effects, thus achieving effective prevention and treatment of RSV infection.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Disclosed herein are compositions and methods for controlling respiratory syncytial virus (RSV) infection. In certain embodiments, vaccines and pharmaceutical compositions comprise or encode RSV G proteins comprising the mutations or fusion protein arrangements disclosed herein. In certain embodiments, viral particles / virus-like particles, nucleic acids, vectors, or attenuated RSV vaccines are used in the methods reported herein.
Need to check novelty before this filing date? Find Prior Art